New COVID-19 vaccine candidate hAd5-COVID-19, which combines internal nuclear casing (N) and external prickly (S) proteins: the patient has been vaccinated.

Immunotherapy companies ImmunityBio and Nant Kwest announced today that the first patient has been vaccinated in a Phase I clinical trial of hAd5-COVID-19.
hAd5-COVID-19 is a new COVID-19 vaccine candidate that combines the virus's internal nuclear shell (N) and external protrusion (S) proteins, and hAd5-COVID-19 has been engineered to activate T-cells and antibodies against SARS-CoV-2.
is a novel COVID-19 vaccine that uses a second-generation adenovirus to deliver a variety of proteins such as SARS-CoV-2.
Phase I trial, currently being conducted at Hoag Hospital in California, is currently recruiting healthy adults under the age of 55 to test the safety of the vaccine candidates.
Patrick Soon-Shiong, Chairman and CEO of ImmunityBio and Nat Kwest, said, "Our candidate vaccine hdA5-COVID-19 has both a nuclear crust protein inside the virus particles and a prickly protein on the surface of the virus.
We believe this dual mechanism is a key advantage that may stimulate T-cell-mediated and antibody-mediated immunity against SARS-CoV-2, which is an important difference from other candidates with only prickly proteins."
.